These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small interfering RNA.
    Author: Cai L, Zhang G, Tong X, You Q, An Y, Wang Y, Guo L, Wang T, Zhu D, Zheng J.
    Journal: Eur J Obstet Gynecol Reprod Biol; 2010 Jan; 148(1):73-80. PubMed ID: 19880237.
    Abstract:
    OBJECTIVE: Signal transducer and activator of transcription 3 (STAT3) are constitutively activated in a variety of cancers and it is a common feature of ovarian cancer. Thus, STAT3 represents a promising molecular target for tumor therapy. We applied a DNA vector-based STAT3-specific RNA interference approach which specifically blocks over-activated STAT3, to treat human ovarian cancer cells, and evaluated the cellular proliferation ability and investigated the molecular mechanisms in vitro. STUDY DESIGN: A DNA vector-based RNA interference approach was used to knockdown STAT3 expression in human ovarian cancer cells in vitro. RESULTS: The STAT3 siRNA down-regulated the expression of cyclin D1, survivin, and VEGF in ovarian cancer cells both at transcription and translation levels. Inhibition of STAT3 and its related genes was accompanied by growth suppression and induction of apoptosis in cancer cells in vitro. CONCLUSIONS: These data indicate that STAT3 signaling is a promising molecular target for ovarian cancer therapy.
    [Abstract] [Full Text] [Related] [New Search]